AnnumeVitality Lab

Losing weight.
What happens to lean mass?

The published COURAGE report examines body composition during semaglutide treatment. Its findings differ by regimen, and scan changes do not establish better strength or function.

The short version

COURAGE is now published in The Lancet. The one-year 75 mg trevogrumab comparison favored lean-mass preservation; the 25 mg estimate was less certain. A separate three-drug regimen raised safety concerns. These are investigational combinations. [4]

What the published report adds

The November 11 report studied adults aged 18–80 with obesity. Part A tested higher doses for 26 weeks before a withdrawal phase; part B tested lower doses for 52 weeks. Analyses included randomized participants who received study drug. [4]

At 52 weeks, the estimated lean-mass difference favoring the 75 mg group was 3.1 percentage points (95% CI 1.3–4.9) compared with semaglutide plus placebo. For 25 mg it was 1.5 points (−0.3 to 3.3); that interval includes no difference. Neither part B group showed significantly greater weight loss. [4]

Safety differs by regimen

In part A's semaglutide/trevogrumab/garetosmab group, 14/149 participants had serious adverse events and 48/149 discontinued treatment. Two deaths occurred in that group; no causal association was identified. These findings must not be assigned to the lower-dose two-drug groups. [4]

This update uses the published author abstract. Full methods and supplementary tables were not accessible for this review, so missing-data and multiplicity details remain unassessed. Regeneron funded the study.

Why this matters

Muscle helps us get out of a chair, climb stairs and carry groceries. Keeping muscle and strength becomes especially important as we age. [3]

That makes the question behind this study easy to understand: when someone loses weight, what are they losing—and what are they keeping?

What changed after one year?

The chart below retains the October 1 sponsor-reported estimates for the lower-dose, 52-week part of COURAGE. Both groups received semaglutide. The published uncertainty estimates above add important context. [1]

Lean mass lost over 52 weeksPercentage of starting lean mass · A shorter bar means less loss.
Semaglutide + placebo7.3%
Semaglutide + trevogrumab 75 mg study group4.2%

Measured by DXA body-composition scans. These are group averages, not an individual prediction. [1]

The difference is 3.1 percentage points, or about 43% less lean-mass loss relative to the comparison group. Some lean mass was still lost.

And the “almost 70%” finding?

Regeneron reported that figure from a separate MRI analysis of participants with usable scans; it was not verified in the published abstract used for this update. The 75 mg group had 68.9% less thigh-muscle volume loss than the comparison group. It does not mean a 70% increase in muscle. [1]

Keep the measurements separate: “lean mass” includes muscle and other tissue; the MRI analysis looked specifically at thigh muscle volume. Neither number, on its own, tells us how much stronger someone became.

What we still need to know

Better scan results are encouraging. The practical questions are whether people also become stronger, move more easily and stay healthier over time. Those benefits cannot be assumed from these numbers.

Trevogrumab remains experimental. COURAGE is a randomized Phase 2 study designed to examine both benefits and safety. [2] The November 11 publication adds peer-reviewed reporting, but the full methods and supplement still need review before expanding this summary. [4]

Look closer at the study

The 52-week comparison used semaglutide 2.4 mg with placebo or trevogrumab 25 mg or 75 mg. These are trial doses, not instructions for use. [1]

Change in lean mass at 52 weeks
Added to semaglutideAverage change
Placebo−7.3%
Trevogrumab 25 mg−5.8%
Trevogrumab 75 mg−4.2%

Common reported side effects included nausea, constipation, diarrhea and vomiting. A one-year trial cannot settle long-term safety. [1]

This table covers the lower-dose, year-long comparison. The separate higher-dose three-drug safety findings are described above; the groups and timepoints should not be pooled.

A useful question to take away

“If I’m losing weight, how are we checking my strength and physical function—not just the number on the scale?”

This article explains research. Decisions about your treatment belong in a conversation with your clinician.

Read the sources

  1. Regeneron’s COURAGE resultsOctober 1, 2026 · Sponsor announcement with the DXA and MRI results.
  2. COURAGE study registrationClinicalTrials.gov · NCT06299098 · Study design and experimental treatments.
  3. Why muscle and strength matter as we ageNational Institute on Aging · Background reading.
  4. Mosenzon and colleagues: published COURAGE reportThe Lancet · November 11, 2026 · DOI: 10.1016/S0140-6736(26)01953-7. Published author abstract verified via NCBI; full text and supplement not reviewed.

Publication and safety update checked November 12, 2026. The earlier chart and MRI figures remain attributed to the October 1 sponsor announcement. Prepared with AI assistance; no article-specific physician review is claimed. Editorial policy.